跳至主要内容
临床试验/NCT00210093
NCT00210093已完成1 期

A Single-Center, Randomized, Crossover Pharmacokinetic Evaluation of the Effect of Single Doses of Intravenous INS37217, Nasally Inhaled INS37217 and Orally Inhaled INS37217 Solution in Healthy Volunteers

Merck Sharp & Dohme LLC0 个研究点目标入组 12 人开始时间: 2003年4月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
12
主要终点
plasma concentrations of INS37217

研究概览

简要总结

The purpose of this trial is to characterize the pharmacokinetics of INS37217 following intravenous, intranasal, and inhalation administration and to calculate the relative bioavailability of INS37217 when administered via oral or nasal inhalation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

接受健康志愿者

入选标准

  • Are current nonsmokers or previous smokers who have not smoked within 6 months and who do not have greater than or equal to a 10 pack-year history of tobacco use
  • Are within 20% of their ideal body weight
  • Are healthy on the basis of a pre-trial physical examination

排除标准

  • History or suspicion of recent alcohol, barbiturate, amphetamine or narcotic abuse or a positive urine drug test at study screening
  • History of cardiac arrhythmias, any pathological abnormality on the ECG, bronchospasm, diabetes mellitus, thyrotoxicosis, Parkinsonism, asthma, COPD or cardiovascular disease significant drug allergy
  • Subject with a physical obstruction in the nose
  • Use of concomitant medication other than hormonal contraceptives and multi-vitamins
  • Subjects with a current upper respiratory illness or infection for the 2 weeks prior to screening or any chronic respiratory illness

结局指标

主要结局

plasma concentrations of INS37217

次要结局

  • Pilot study - not specified

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

A Pharmacokinetic Evaluation Study in Healthy... | 临床试验